Metotrexato Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This cofactor is required for synthesising DNA, RNA and proteins. By limiting these building blocks, methotrexate hampers the growth of rapidly dividing cells and reduces inflammatory immune activity.

The specific dose of Metotrexato Accord is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Healthcare professionals calculate the appropriate regimen and adjust it as needed during therapy.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential must use effective contraception during treatment and for a period after stopping the drug. Breastfeeding is also discouraged, as methotrexate can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metotrexato Accord is a methotrexate formulation meeting EU quality standards and is supplied as a sterile injectable. Compared with oral tablets, the injectable route offers predictable bioavailability and is often preferred for rapid disease control or when oral absorption is unreliable. Efficacy is comparable across approved methotrexate brands when used at equivalent doses.

Metotrexato Accord should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vials in their original packaging until use and discard any solution that appears discoloured or cloudy.

The product is supplied as a sterile solution for intra‑arterial, intramuscular or intravenous injection. Administration is performed by qualified healthcare professionals in a clinical setting, following aseptic technique and the dosing instructions provided by the prescriber.

Serious risks include bone‑marrow suppression leading to pancytopenia, severe hepatic injury such as fibrosis or cirrhosis, and pulmonary toxicity presenting as interstitial pneumonitis. Patients should be monitored regularly for blood counts, liver enzymes and respiratory symptoms to detect these complications early.

Methotrexate is contraindicated in patients with known hypersensitivity to the drug, severe renal impairment, active uncontrolled infections, and in women who are pregnant or planning pregnancy without effective contraception. Caution is also advised for individuals with pre‑existing liver disease or significant pulmonary disorders.